MedTrace Logo

A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

NCT05997485 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-03-28

No results posted yet for this study

Summary

The purpose of this study is to collect information on the:

* general information of a group of people such as their age, sex, and other facts.
* clinical information of the patients such as any other illness before having COVID 19.

In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.

This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.

This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.

The study will include patient information of those who:

* are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023.
* are 18 years of age or older.
* are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.

Conditions

  • COVID-19 Drug Treatment

Interventions

DRUG

Nirmatrelvir/Ritonavir

Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2024-06-30
Completion
2024-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05997485 on ClinicalTrials.gov